CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: February 27, 2012
Result type: Reports
Project Number: SR0271
Product Line: Common Drug Review

Generic Name: Rivaroxaban

Brand Name: Xarelto

Manufacturer: Bayer Inc.

Indications: Deep-Vein Thrombosis (treatment), without Symptomatic Pulmonary Embolism

Submission Type: New Indication

Project Status: Complete

Date Recommendation Issued: August 16, 2012

Recommendation Type: List with clinical criteria and/or conditions